Abstracts tagged "B cell memory"

Abstract Number: 1087 • 2016 ACR/ARHP Annual Meeting
Nonmemory B Cell Signature Alterations in Belimumab Patients
Karina Marianne D. Torralba¹, Vaneet Sandhu², Abigail Benitez¹ and Sheila Lezcano³, ¹Rheumatology, Loma Linda University, Loma Linda, CA, ²Division of Rheumatology, Loma Linda University, Loma Linda, CA, ³Rheumatology, Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: Insight into B cell subset dynamics and homeostasis can provide a biological rationale for use of B cell targeted therapies in SLE patients. Using…
Abstract Number: 1081 • 2016 ACR/ARHP Annual Meeting
The CRL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Inhibits BAFF-Mediated Plasmablast Differentiation and Immunoglobulin Secretion from Class Switched CD27+IgD- Memory and Lupus-Associated CD27-IgD- Double Negative B-Cells
Yumi Nakayama¹, Jolanta Kosek¹, Lori Capone², Peter H. Schafer³ and Garth Ringheim¹, ¹Inflammation and Immunology Translational Development, Celgene Corporation, Summit, NJ, ²Celgene Corporation, Summit, NJ, ³Department of Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: Changes in the ratio of circulating memory, naive, and double negative CD27-IgD- B cell subsets are associated with a higher disease activity index in…
Abstract Number: 1954 • 2014 ACR/ARHP Annual Meeting
Successfull Long-Term Depletion of Memory Plasma Cells Requires a Combined Depletion of Plasma Cells and Their Precurors in NZB/W Mice
Adriano Taddeo¹, Laleh Khodadadi¹, Qingyu Cheng², Andreas H. Radbruch¹, Falk Hiepe³ and Bimba F. Hoyer², ¹Deutsches Rheumaforschungszentrum, Berlin, Germany, ²Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Germany, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany
Background/Purpose: Autoantibodies contribute significantly to the pathogenesis of systemic lupus erythematosus (SLE). The long-lived plasma cells (LLPC) secreting such autoantibodies are unfortunately refractory to conventional…
Abstract Number: 996 • 2014 ACR/ARHP Annual Meeting
Memory B Cell Subtype Modulation in Patients with Rheumatoid Arthritis
Zafar Mahmood¹, Marc Schmalzing², Thomas Dörner³ and Hans-Peter Tony², ¹Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ³Charité Universitätmedizin Berlin and DRFZ, Berlin, Germany
Background/Purpose . Memory B cells have been shown to play important roles in the pathogenesis of rheumatoid arthritis (RA). With the advent of B cell…
Abstract Number: 448 • 2014 ACR/ARHP Annual Meeting
Citrulline-Specific Autoimmunity Resides in Quiescent Circulating Memory B Cells in Rheumatoid Arthritis
Adam Pelzek, Caroline Grönwall, Jeffrey D. Greenberg and Gregg J. Silverman, Medicine, New York University School of Medicine, New York, NY
Background/Purpose . The detection of anti-citrullinated protein antibodies (ACPA) aids RA diagnosis, while B cell depletion by anti-CD20 can provide clinical benefits. We therefore undertook…
Abstract Number: 1776 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment Of Adult and Childhood Myositis
Rohit Aggarwal¹, Chester V. Oddis², Erich R Wilkerson³, Diane Koontz⁴, Ilinca D. Metes⁵, Ann M. Reed⁶, Dana P. Ascherman⁷ and Marc C. Levesque⁸, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: B cell subset numbers, especially lower memory B (Bmem) cells, predict clinical responsiveness to rituximab in several diseases including pemphigus and rheumatoid arthritis (RA).…
Abstract Number: 447 • 2013 ACR/ARHP Annual Meeting
High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis
Claire I. Daien^1,2, Sarah Gailhac³, Thibault Mura⁴, Bernard Combe², Michael Hahne¹ and Jacques Morel⁵, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Igmm UMR3555, CNRS, Montpellier, France, ⁴CIC, Hopital Gui De Chauliac, Montpellier, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Tumor necrosis factor (TNF) inhibitors (TNFi) are effective treatments for rheumatoid arthritis (RA). Some reports suggested that TNFi affect B cell homeostasis. We studied…
Abstract Number: 25 • 2013 ACR/ARHP Annual Meeting
SLE Flares Are Characterized By Generalized Polyclonal Expansions Of Antibody Secreting Cells Without Preference For Autoimmune Responses
H. Travis Ichikawa, Medicine, Emory University, Atlanta, GA
Background/Purpose: Increased circulating antibody secreting cells (ASC), including both CD138- plasmablasts and CD138+ plasma cells (PB/PC), correlate with SLE activity and are prominent during Lupus…
Abstract Number: 31 • 2013 ACR/ARHP Annual Meeting
IgD- CD27- B Cells From Systemic Lupus Erythematous Patients Have Increased Expression Of Genes Involved In RNA Sensing and Toll-Like Receptor 3 Signaling Pathways
Scott Jenks¹, Edward Ramos² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Biology, Emory University, Atlanta, GA, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: SLE patients have perturbations in B cell subsets including a large expansion of IgD-CD27- B cells (DN) in patients with active disease. Patients also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].